Grant Received from the Bill & Melinda Gates Foundation to Fund Development of Affordable TherapeuticsJUPITER, Fla., Nov. 21, ...

Highlights Revenue Milestones and Expands Alternative Protein & Pharmaceutical Partnerships with Dapibus™ & C1 Technology ...

Dyadic International has secured a $3 million grant from the Bill & Melinda Gates Foundation to develop cost-effectiv ...

After hours: November 29 at 4:22 PM EST Loading Chart for DYAI ...

Dyadic international was awarded a $3 million grant from the Bill & Melinda Gates Foundation to fund the development of ...

Dyadic International, Inc. (NASDAQ:DYAI) Q3 2024 Earnings Call Transcript November 16, 2024 Operator: Operator: Good evening, and welcome to Dyadic International Q3 2024 Conference Call.

Dyadic International (DYAI) announced that it has been awarded a $3M grant from the Gates Foundation for the cell line development of monoclonal antibodies targeting respiratory syncytial virus and ...

“We believe our third quarter achievements underscore Dyadic’s commitment to leveraging our proprietary Dapibus™ and C1 microbial protein production platforms to drive immediate and ...

Investor Conference call at 5:00 p.m. ET today. JUPITER, Fla., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Dyadic International, Inc. ("Dyadic”, "we”, "us”, "our”, or the "Company”) (NASDAQ: DYAI), a ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...